The presence and abundance of tumor-infiltrating lymphocytes (TILs) before NAC play crucial roles in the induction of therapeutic effects and favorable prognostic outcomes after chemotherapy for HER-2-positive and TN breast cancers [11]. This evidence concerns the gene ERBB2 and breast carcinoma.